Semaglutide vs. Tirzepatide: Are We Closing the Gap?
Can higher doses of semaglutide really deliver better results, without the side effects? In this episode of Docs Who Lift, Dr. Spencer Nadolsky and Dr. Karl Nadolsky Jr. sit down with Canadian obesity expert and clinical trialist Dr. Sean Wharton to break down the latest data from the STEP-UP trial. They dig into the science behind tripling the dose of semaglutide, how it compares to drugs like tirzepatide, and what it means for the future of obesity treatment.
Audio is streamed directly from the publisher (injector.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
How the STEP-UP trial came to life, and what made the 7.2mg dose possible
What the data actually says about weight loss and side effects at higher doses
Why trial design, pharmacokinetics, and estimands matter more than you think
What’s coming next in obesity meds: duals, triples, and even antagonists
The real talk on intermittent fasting, access issues, and preaching vs. science
Sign up for Dr. Spencer''s Clinic
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.